{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T05:08:33Z","timestamp":1738645713483,"version":"3.35.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.leukres.2024.107633","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T22:59:31Z","timestamp":1732661971000},"page":"107633","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Long-term follow-up of zimberelimab in relapsed or refractory classic Hodgkin lymphoma: Insights from the phase \u2161 YH-S001-04 clinical trial"],"prefix":"10.1016","volume":"149","author":[{"given":"Suisui","family":"Kan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Ke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huilai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongmei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongsheng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aimin","family":"Zang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junyuan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuogang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xielan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunhong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shenmiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinsheng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zonghong","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ningjing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingzhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.leukres.2024.107633_bib1","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT Scan in advanced hodgkin\u2019s lymphoma[J\/OL]","volume":"374","author":"Johnson","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.leukres.2024.107633_bib2","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response\u2013adapted treatment in stage I and II hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 Trial[J\/OL]","volume":"35","author":"Andr\u00e9","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.leukres.2024.107633_bib3","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(20)30601-X","article-title":"PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial[J\/OL]","volume":"22","author":"Borchmann","year":"2021","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.leukres.2024.107633_bib4","doi-asserted-by":"crossref","first-page":"e398","DOI":"10.1016\/S2352-3026(21)00101-0","article-title":"PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial[J\/OL]","volume":"8","author":"Kreissl","year":"2021","journal-title":"Lancet Haematol."},{"issue":"11","key":"10.1016\/j.leukres.2024.107633_bib5","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/ajh.26717","article-title":"Hodgkin lymphoma: 2023 update on diagnosis, risk-stratification, and management[J\/OL]","volume":"97","author":"Ansell","year":"2022","journal-title":"Am. J. Hematol."},{"issue":"10310","key":"10.1016\/j.leukres.2024.107633_bib6","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S0140-6736(20)32207-8","article-title":"Classical hodgkin lymphoma[J\/OL]","volume":"398","author":"Brice","year":"2021","journal-title":"Lancet (Lond., Engl. )"},{"issue":"1","key":"10.1016\/j.leukres.2024.107633_bib7","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2012.03.011","article-title":"The role of high dose chemotherapy and autologous stem-cell transplantation in peripheral T-cell lymphoma: a review of the literature and new perspectives[J\/OL]","volume":"39","author":"Yared","year":"2013","journal-title":"Cancer Treat. Rev."},{"issue":"11","key":"10.1016\/j.leukres.2024.107633_bib8","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.3109\/10428194.2013.798868","article-title":"Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant[J\/OL]","volume":"54","author":"Arai","year":"2013","journal-title":"Leuk. Lymphoma"},{"issue":"25","key":"10.1016\/j.leukres.2024.107633_bib9","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2018-07-861641","article-title":"Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse[J\/OL]","volume":"132","author":"Moskowitz","year":"2018","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.leukres.2024.107633_bib10","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II checkMate 205 trial[J\/OL]","volume":"36","author":"Armand","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.leukres.2024.107633_bib11","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic hodgkin lymphoma[J\/OL]","volume":"35","author":"Chen","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.leukres.2024.107633_bib12","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/S2352-3026(18)30192-3","article-title":"Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial[J\/OL]","volume":"6","author":"Shi","year":"2019","journal-title":"Lancet Haematol."},{"issue":"24","key":"10.1016\/j.leukres.2024.107633_bib13","doi-asserted-by":"crossref","first-page":"7363","DOI":"10.1158\/1078-0432.CCR-19-1680","article-title":"A single-arm, multicenter, phase ii study of camrelizumab in relapsed or refractory classical hodgkin lymphoma[J\/OL]","volume":"25","author":"Song","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.leukres.2024.107633_bib14","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41375-019-0545-2","article-title":"Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study[J\/OL]","volume":"34","author":"Song","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2024.107633_bib15","article-title":"Penpulimab for relapsed or refractory classical hodgkin lymphoma: a multicenter, single-arm, pivotal phase I\/II trial (AK105-201)[J\/OL]","volume":"12","author":"Song","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.leukres.2024.107633_bib16","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejca.2021.07.021","article-title":"Efficacy and safety of GLS-010 (zimberelimab) in patients with relapsed or refractory classical Hodgkin lymphoma: a multicenter, single-arm, phase II study[J\/OL]","volume":"164","author":"Lin","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"10.1016\/j.leukres.2024.107633_bib17","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S1470-2045(21)00005-X","article-title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study[J\/OL]","volume":"22","author":"Kuruvilla","year":"2021","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.leukres.2024.107633_bib18","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory hodgkin\u2019s lymphoma[J\/OL]","volume":"372","author":"Ansell","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.leukres.2024.107633_bib19","doi-asserted-by":"crossref","first-page":"6266","DOI":"10.1182\/bloodadvances.2023010334","article-title":"Nivolumab for relapsed\/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study[J\/OL]","volume":"7","author":"Ansell","year":"2023","journal-title":"Blood Adv."},{"issue":"12","key":"10.1016\/j.leukres.2024.107633_bib20","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1182\/bloodadvances.2019001367","article-title":"KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure[J\/OL]","volume":"4","author":"Armand","year":"2020","journal-title":"Blood Adv."},{"issue":"2","key":"10.1016\/j.leukres.2024.107633_bib21","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41375-019-0545-2","article-title":"Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study[J\/OL]","volume":"34","author":"Song","year":"2020","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.leukres.2024.107633_bib22","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1158\/1078-0432.CCR-21-2023","article-title":"Tislelizumab for relapsed\/refractory classical hodgkin lymphoma: 3-year follow-up and correlative biomarker analysis[J\/OL]","volume":"28","author":"Song","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2024.107633_bib23","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.2147\/DDDT.S136988","article-title":"Lugano 2014 criteria for assessing FDG-PET\/CT in lymphoma: an operational approach for clinical trials[J\/OL]","volume":"11","author":"Van Heertum","year":"2017","journal-title":"Drug Des., Dev. Ther."},{"issue":"1","key":"10.1016\/j.leukres.2024.107633_bib24","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41392-023-01600-7","article-title":"Long-term survival benefit of anti-PD-1 therapy in patients with relapsed or refractory classical Hodgkin lymphoma[J\/OL]","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"10","key":"10.1016\/j.leukres.2024.107633_bib25","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1182\/blood.2022019386","article-title":"Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed\/refractory classical Hodgkin lymphoma[J\/OL]","volume":"142","author":"Armand","year":"2023","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.leukres.2024.107633_bib26","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","article-title":"Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma[J\/OL]","volume":"128","author":"Chen","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2024.107633_bib27","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S1470-2045(21)00005-X","article-title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study[J\/OL]","volume":"22","author":"Kuruvilla","year":"2021","journal-title":"Lancet Oncol."},{"issue":"14","key":"10.1016\/j.leukres.2024.107633_bib28","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1182\/blood.2019000324","article-title":"Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087[J\/OL]","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212624001991?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212624001991?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T09:09:12Z","timestamp":1738573752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212624001991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":28,"alternative-id":["S0145212624001991"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107633","relation":{},"ISSN":["0145-2126"],"issn-type":[{"type":"print","value":"0145-2126"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term follow-up of zimberelimab in relapsed or refractory classic Hodgkin lymphoma: Insights from the phase \u2161 YH-S001-04 clinical trial","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107633","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107633"}}